Effect of naltrexone during extinction of alcohol-reinforced responding and during repeated cue-conditioned reinstatement sessions in a cue exposure style treatment.
The ability of alcohol-related cues to promote craving can be attenuated independently by giving the opioid antagonist naltrexone (NTX) or by subjecting alcohol-dependent patients to a cue exposure treatment. The effects of cue exposure treatment may be enhanced if conducted in the presence of NTX. The purpose of these experiments was to determine if NTX given during extinction of responding for alcohol in rats would alter cue-conditioned reinstatement of responding and to determine if NTX, paired with repeated cue-conditioned reinstatement, would reduce subsequent cue-conditioned reinstatement or reacquisition of self-administration in the absence of NTX. Rats lever pressed for alcohol in the presence of an olfactory cue. Visual and auditory stimuli were presented during alcohol delivery. In the first experiment, rats were injected with saline or 3mg/kg NTX prior to extinction sessions followed by cue-conditioned reinstatement tests. In the second experiment, extinction was followed by cue-conditioned reinstatement sessions presented twice per week. The rats received saline or NTX (3 and 10mg/kg) prior to several sessions. All rats received reinstatement tests with and without a pretreatment of NTX followed by reacquisition of alcohol self-administration. NTX had no effect on responding during extinction or on subsequent cue-conditioned reinstatement. Only 10mg/kg NTX reduced responding during the twice weekly reinstatement sessions. The twice weekly NTX treatment had no effect on subsequent cue-conditioned reinstatement in the absence of NTX. Reacquisition of responding for alcohol was reduced in the group receiving saline during repeated reinstatement sessions, whereas this effect was blocked in the NTX group. These findings support the notion that NTX given during a brief abstinence period (i.e., extinction) has minimal effects on future sensitivity to alcohol cues and alcohol consumption. NTX given during the repeated alcohol cue exposure does not alter the subsequent incentive value of alcohol cues in the absence of NTX or enhance the beneficial effects of cue exposure treatment.
Williams
Keith L
KL
Department of Psychology, Oakland University, Rochester, MI 48309, USA. william9@oakland.edu
Schimmel
Jasmine S
JS
D000428:Alcohol Drinking / Q000188:drug therapy* / Q000523:psychology; D000818:Animals; D003213:Conditioning, Psychological / Q000187:drug effects* / Q000502:physiology; D003463:Cues; D000431:Ethanol / Q000008:administration & dosage*; D005108:Extinction, Psychological / Q000187:drug effects* / Q000502:physiology; D008297:Male; D009271:Naltrexone / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D020318:Rats, Long-Evans
D000431:Ethanol; D009271:Naltrexone
J Pharmacol Exp Ther. 1971 Sep;178(3):562-4
5571904
Alcohol Clin Exp Res. 2006 May;30(5):860-5
16634855
JAMA. 2006 May 3;295(17):2003-17
16670409
Psychopharmacology (Berl). 2002 Oct;163(3-4):327-44
12373434
Alcohol Alcohol. 2001 Jan-Feb;36(1):2-10
11139409
Pharmacol Biochem Behav. 1985 Nov;23(5):797-802
4080766
Psychopharmacology (Berl). 2003 Jul;168(1-2):208-215
12664190
Neuropsychopharmacology. 2002 Sep;27(3):391-9
12225696
Alcohol Clin Exp Res. 2007 Feb;31(2):260-4
17250617
Alcohol Clin Exp Res. 2007 Jul;31(7):1179-87
17451401
Psychopharmacology (Berl). 1999 Jun;144(3):213-9
10435387
J Clin Psychopharmacol. 2006 Dec;26(6):610-25
17110818
Alcohol Res Health. 2000;24(2):132-9
11199280
Ann Med. 1998 Aug;30(4):406-11
9783840
Alcohol Clin Exp Res. 1999 Nov;23(11):1761-71
10591592
Alcohol Clin Exp Res. 2001 Jul;25(7):1006-11
11505025
Alcohol Clin Exp Res. 2001 Nov;25(11):1634-47
11707638
J Consult Clin Psychol. 1997 Oct;65(5):878-82
9337506
Behav Res Ther. 1983;21(4):435-46
6626114
Eur J Pharmacol. 1999 Jun 25;374(3):321-7
10422776
J Consult Clin Psychol. 1994 Aug;62(4):809-17
7962885
Alcohol Clin Exp Res. 1999 Aug;23(8):1386-94
10470982
Neuropsychopharmacology. 1999 May;20(5):471-9
10192827
Addiction. 2001 Aug;96(8):1161-74
11487422
Alcohol Alcohol. 2000 Nov-Dec;35(6):537-47
11093959
Alcohol Clin Exp Res. 2001 Oct;25(10):1414-9
11696659
Exp Clin Psychopharmacol. 1999 Aug;7(3):266-73
10472515
J Abnorm Psychol. 1987 May;96(2):122-6
3584660
J Clin Psychopharmacol. 2002 Dec;22(6):592-8
12454559
Behav Res Ther. 1980;18(4):319-25
7436979
J Pharmacol Exp Ther. 1990 Jan;252(1):8-14
2405152
Alcohol Clin Exp Res. 1989 Jun;13(3):392-8
2665554
Alcohol Clin Exp Res. 2007 Jan;31(1):39-47
17207100
Arch Gen Psychiatry. 1992 Nov;49(11):876-80
1345133
J Consult Clin Psychol. 1994 Jun;62(3):620-6
8063989
N Engl J Med. 2001 Dec 13;345(24):1734-9
11742047
J Neurosci. 2002 Sep 15;22(18):7856-61
12223538
J Abnorm Psychol. 2000 Nov;109(4):738-42
11195999
J Clin Psychopharmacol. 2001 Jun;21(3):287-92
11386491
Psychopharmacology (Berl). 1997 Jan;129(1):72-8
9122366
Behav Neurosci. 1990 Oct;104(5):725-33
2244981
Alcohol Clin Exp Res. 2004 Apr;28(4):558-65
15100606
Brain Res Bull. 2005 Jan 15;64(5):417-24
15607829
Eur J Pharmacol. 1999 Jun 25;374(3):315-9
10422775
Psychopharmacology (Berl). 1999 Aug;145(4):360-9
10460312
Neuropsychopharmacology. 2004 Feb;29(2):393-402
14679386
Alcohol Clin Exp Res. 1999 Nov;23(11):1751-60
10591591
Pharmacol Biochem Behav. 1982 Jun;16(6):1013-5
7111345
Eur J Pharmacol. 2005 Dec 28;528(1-3):110-8
16324694
J Abnorm Psychol. 1988 May;97(2):133-52
3290304
Neuroscience. 2006;139(3):877-87
16516392
Arch Gen Psychiatry. 1992 Nov;49(11):881-7
1444726
Addict Behav. 1983;8(1):1-10
6880920
Neuropsychopharmacology. 2003 Aug;28(8):1463-71
12700689
J Clin Psychopharmacol. 2003 Jun;23(3):294-304
12826991
Alcohol Clin Exp Res. 1999 Aug;23(8):1331-5
10470975
Drug Alcohol Rev. 1990;9(2):155-68
16840135
Alcohol Clin Exp Res. 2001 Sep;25(9):1335-41
11584154